Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals Inc (NQ: AVIR )

3.760 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.760
Bid (Size) 3.500 (7)
Ask (Size) 3.990 (2)
Prev. Close 3.760
Today's Range 3.760 - 3.760
52wk Range 2.765 - 4.600
Shares Outstanding 83,399,377
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Recap: Atea Pharmaceuticals Q4 Earnings
Via Benzinga

Performance

YTD
+17.13%
+17.13%
1 Month
-6.00%
-6.00%
3 Month
+9.94%
+9.94%
6 Month
+25.33%
+25.33%
1 Year
+11.57%
+11.57%

More News

Read More
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Earnings Preview
Via Benzinga
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals's Earnings Outlook
Via Benzinga
Earnings Preview For Atea Pharmaceuticals
Via Benzinga
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Via Benzinga
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.